Valuation
- Market cap
- 2,000
- Revenue TTM
- $0
- Net income TTM
- $-114,530,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- -1.27
Trading
- Volume
- 1,200
- Avg volume
- 8,906
- Day's range
- $0.00 – $0.00
- Shares out
- 18,840,000
- Stochastic %K
- 0%
- Beta
- 1.34
- Analysts
- —
- Price target
- $10.00
Company profile
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Vei...
Show more
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 617 577 0300
- Address
- 600/700, One Kendall Square, Suite 7-201, Cambridge, United States
Latest news
No headlines yet.
Stocktwits
PenkeInvesting
Jun 23, 8:10 AM
Fundamental analysis of
$EVLO (Evelo Biosciences, Inc.) based on financial data and reported results. #EVLO
MGeronimo
Aug 14, 3:57 AM
$EVLO EASILY THE EASIEST 60k I have made
0 replies
NVDAMillionaire
Mar 26, 1:40 AM
$EVLO Interesting biotech play. SINTAX platform looks promising but recent clinical failures raise red flags. Watching closely for strategic alternatives or potential partnership. Might be a speculative entry for risk-tolerant investors. standout article: https://beyondspx.com/article/evelo-biosciences-inc-evlo-exploring-the-potential-of-sintax-medicines
0 replies
NVDAMillionaire
Jan 17, 5:26 PM
$EVLO Evelo Biosciences, Inc. (NASDAQ:EVLO): Navigating the Challenges of a Development-Stage Biotech https://beyondspx.com/article/evelo-biosciences-inc-evlo-navigating-the-challenges-of-developing-a-novel-therapeutic-approach
0 replies
NVDAMillionaire
Dec 5, 4:28 AM
$EVLO Evelo Biosciences, Inc. (EVLO): Navigating the Challenges of Developing a Novel Therapeutic Approach https://beyondspx.com/article/evelo-biosciences-inc-evlo-navigating-the-challenges-of-developing-a-novel-therapeutic-approach
0 replies
ganta7
Nov 7, 3:49 PM
$EVLO Nancy we have the cream for wrinkle skin
Lfg
0 replies
GreenSky_
Aug 6, 12:06 PM
$MCRB Nestlé knows the remaining pipeline is too risky to acquire the whole company, it's likely to fail. MCRB was founded by Flagship Pioneering so be careful here, this may end up like
$EVLO and
$KLDO.P (failed Flagship Pioneering's microbiome companies).
0 replies
bdog_stayloyal
Apr 1, 2:45 PM
$EVLO I will be very happy if I see this hit
$0.07 today.
0 replies
